IN8bio (NASDAQ:INAB) Earns “Buy” Rating from HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $8.00 price target on the stock.

IN8bio Stock Performance

Shares of NASDAQ INAB opened at $0.31 on Wednesday. The firm has a 50 day moving average of $0.28 and a 200 day moving average of $0.36. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $22.24 million, a price-to-earnings ratio of -0.41 and a beta of 0.05. IN8bio has a 12-month low of $0.22 and a 12-month high of $1.74.

IN8bio (NASDAQ:INAB) last announced its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, research analysts anticipate that IN8bio will post -0.56 earnings per share for the current year.

Institutional Trading of IN8bio

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp raised its position in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the quarter. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.